Effect of a New Optimized Plant Ingredient on the Plant Protein of Seniors at Cardio-metabolic Risk

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age65+
SponsorUniversity Hospital, Clermont-Ferrand

About this trial

The aim of the study is to compare the use of amino acids in whole-body protein metabolism in elderly consumers at risk of metabolic syndrome, after ingestion of 2 foods differing only in the nature of their proteins (optimized blend of vegetable proteins versus milk proteins).

The protocol consists in studying the postprandial evolution of protein metabolism. Two products will be tested: one based on dairy proteins, the other on an optimized blend of vegetable proteins).

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Waist circumference > 94cm

Triglycerides > 1.5 g/L or HDL cholesterol < 0.4 g/L

Fasting blood glucose < 1.26g/L

Biological profile considered compatible with study participation,

Disqualifiers

Subjects on special diets (vegetarian, vegan, etc.),

Subject showing a weight loss ≥ 5% in 1 month or ≥ 10% in 6 months compared to usual weight.

Subject refusing to stop taking dietary supplements for the duration of the study,

Subject refusing to consume any of the proposed products,

Trial design

Design model

Crossover

Treatments tested in this trial

  • Test meal with plant protein

    Other intervention

    The plant protein blend is made up of 5 protein ingredients for which the food grade is guaranteed: a rice protein isolate, a potato protein isolate, a lupin protein isolate, a corn protein isolate.

  • Test meal with milk protein

    Other intervention

    The milk protein product is a food-grade protein isolate.

Treatment groups

10 Participants
are divided into 2 treatment groups
Group A: Plant proteinsExperimental treatment 1 intervention
Group B: Milk proteinActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Whole body protein metabolism

Body leucine flux kinetics: oxidation, protein synthesis

Time frame
8 months (including mass spectrometry analysis and calculations)

Secondary outcomes

1

Satiety effect

Satiety-enhancing effect of proteins, assessed using a visual analog scale

Time frame
12 months
2

Evolution of blood parameters related to satiety

Plasma concentrations of glucose, insulin, ghrelin, cholecystokinin, glucagon-like-peptide (GLP1), peptide YY (PYY) and amino acids

Time frame
12 months
3

Product tolerance

Product tolerance assessed by questionnaire

Time frame
12 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital, Clermont-Ferrand

Lead sponsor

Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement

Collaborator

This trial is not recruiting at the moment. You can still explore other options: